Zobrazeno 1 - 10
of 90
pro vyhledávání: '"S. Rendell"'
Autor:
Marc S. Rendell
Publikováno v:
Expert Review of Endocrinology & Metabolism. 18:81-94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34ca7f95cb04e8c08e49948dee55ed47
https://doi.org/10.1080/17446651.2023.2168643
https://doi.org/10.1080/17446651.2023.2168643
Autor:
L.M. Nic Lochlainn, M. Perut, E. Wootton, Jayani Pathirana, N. Yusuf, Theresa Diaz, M. Ahun, S. Rendell, S. Merten, Joachim Hombach, Carsten Mantel, Allisyn C. Moran, Özge Tunçalp, Nathalie Roos, Philipp Lambach, Michelle L. Giles, Flor M. Munoz
Publikováno v:
Vaccine
Objectives To examine the characteristics of existing maternal tetanus immunization programmes for pregnant women in low- and middle-income countries (LMICs) and to identify and understand the challenges, barriers and facilitators associated with mat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::632619c82222122e97af46568cadfc92
http://europepmc.org/articles/PMC7342017
http://europepmc.org/articles/PMC7342017
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Autor:
Sri Harsha Tella, Marc S. Rendell
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 6 (2015)
Glucagon-like polypeptide (GLP-1) receptor agonist treatment has multiple effects on glucose metabolism, supports the β cell, and promotes weight loss. There are now five GLP-1 agonists in clinical use with more in development. GLP-1 treatment typic
Externí odkaz:
https://doaj.org/article/b3dd0b0bde784368942dd7d1e6908cf8
Autor:
Marc S Rendell
Publikováno v:
Drug Design, Development and Therapy. 13:817-824
Gene knockout has been a powerful technique to evaluate the physiologic role of selected gene products. Lexicon pioneered high-throughput gene knockout technology and went further in designing agents to inhibit products of gene expression. Two agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35c835256e1b3e1074de7845eeda7962
https://doi.org/10.2147/dddt.s144556
https://doi.org/10.2147/dddt.s144556
Autor:
Özge Tunçalp, Matthews Mathai, S. Merten, Elizabeth Mason, S. Rendell, Philipp Lambach, Michelle L. Giles, Jayani Pathirana, Joachim Hombach, Allisyn C. Moran, Flor M. Munoz, M. Baye, Nathalie Roos, Theresa Diaz
Publikováno v:
Vaccine
Objectives To map the integration of existing maternal tetanus immunization programmes within antenatal care (ANC) services for pregnant women in low- and middle-income countries (LMICs) and to identify and understand the challenges, barriers and fac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::333e7a8eebb42e86a733b3248199edb1
https://edoc.unibas.ch/77719/
https://edoc.unibas.ch/77719/
Publikováno v:
Journal for Nature Conservation. 53:125779
Little terns in the UK have undergone a population decline of 37 % over the last three decades despite protection efforts at their breeding sites during this time. In 2014, a five-year Little Tern Recovery Project was launched in the UK through the E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec30aa8fddd812368af4652cfda0c93b
https://doi.org/10.1016/j.jnc.2019.125779
https://doi.org/10.1016/j.jnc.2019.125779
Autor:
Marc S. Rendell
Publikováno v:
Expert opinion on drug safety. 16(9)
Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f350a468d6e5b9168678d861c3dbf11
https://pubmed.ncbi.nlm.nih.gov/28678550
https://pubmed.ncbi.nlm.nih.gov/28678550
Autor:
Marc S Rendell
Publikováno v:
Drug Design, Development and Therapy
Insulin degludec has been the product of a sophisticated and systematic biochemical engineering program which began with the release of insulin detemir. The goal was to produce a long-lasting basal insulin with low individual variability. Certainly,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44acf5a85fc57b1ec552fb5e7e6b68c6
https://pubmed.ncbi.nlm.nih.gov/28458515
https://pubmed.ncbi.nlm.nih.gov/28458515
Autor:
Sri Harsha Tella, Marc S. Rendell
Publikováno v:
Expert Opinion on Drug Safety. 14:127-140
Dipeptidyl peptidase inhibitors (DPP-4-i) are highly selective inhibitors of the enzyme DPP-4. They act by increasing levels of incretin hormones, which have potent effects on insulin and glucagon release, gastric emptying, and satiety. Our goal is t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::631b0d30fa88e246f239b47144618269
https://doi.org/10.1517/14740338.2015.977863
https://doi.org/10.1517/14740338.2015.977863
Publikováno v:
Diabetes Management. 4:85-101
SUMMARY Linagliptin is a highly selective inhibitor of the enzyme DPP-4. It is one of several agents of this class now available for treatment of Type 2 diabetes. This review is based on a PubMed search, clinical trials and personal experience with l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8bdd31bdcb62cf2a2f5ec6a2353bbba
https://doi.org/10.2217/dmt.13.55
https://doi.org/10.2217/dmt.13.55